Navigation Links
Shire plc: Change to Director's Details

PHILADELPHIA and DUBLIN, February 5 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces that Mr Matthew Emmens, non-executive Chairman of Shire, has been appointed President of Vertex Pharmaceuticals Incorporated with immediate effect and that Mr Emmens will in addition become Chairman and Chief Executive Officer of Vertex in May 2009 when the current Chief Executive Officer retires.

    This announcement is made pursuant to Listing Rule 9.6.14R.

    Tony Guthrie
    Deputy Company Secretary

    Notes to editors
    Shire plc

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website:

    For further information please contact:

    Investor Relations
    Clea Rosenfeld (Rest of the World)

    Eric Rojas (North America)

    Matthew Cabrey (Specialty Pharma)

    Jessica Cotrone (HGT)

SOURCE Shire plc
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Shire Successfully Settles Former TKT Shareholder Appraisal Rights Litigation
2. Shires New Product Portfolio Delivers Strong Quarterly Performance
3. Change of Name to Shire plc
4. Shire Announces Holding of 81% in Jerini AG and Publication of Offer Document
5. Shire Delivers Strong Quarter: Driven by $243m of New Product Sales (+164% YOY Growth). Revenue Guidance Upgrade.
6. Shire Re-Launches, a Virtual Road Map Providing Information, Tools and Practical Tips About Attention Deficit Hyperactivity Disorder (ADHD)
7. Shire Ltd.: Robin Buchanan to Step Down as Non-Executive Director on Completion of Term of Office
8. Shire Ltd - Second Quarter 2008 Results Date Notification - 31 July 2008
9. Graham Hetherington Appointed Chief Financial Officer and Board Director at Shire
10. Application for Listing of Shire Limited Ordinary Shares
11. Shire Launches Nationwide Adult ADHD Mobile Awareness Tour
Post Your Comments:
(Date:11/27/2015)... 27, 2015 ... of companion diagnostics is one of the ... with pharmaceutical companies and diagnostic manufacturers working ... . --> ... on global cancer biomarkers market spread across ...
(Date:11/25/2015)... -- 2 nouvelles études permettent d , ... entre les souches bactériennes retrouvées dans la plaque ... . Ces recherches  ouvrent une nouvelle voie ... efficace de l,un des problèmes de santé les ...    --> 2 nouvelles études permettent d ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... of Black Aerospace Professionals (OPBAP) has been formalized with the signing of a ... leaders met with OPBAP leaders Capt. Karl Minter and Capt. Albert Glenn Tuesday, ...
(Date:11/24/2015)... ... , ... The United States Golf Association (USGA) today announced Dr. Bruce Clarke, ... annually since 1961, the USGA Green Section Award recognizes an individual’s distinguished service to ... Clarke, of Iselin, N.J., is an extension specialist of turfgrass pathology in the department ...
Breaking Biology Technology:
(Date:11/9/2015)... 9, 2015  Synaptics Inc. (NASDAQ: SYNA ), ... broader entry into the automotive market with a comprehensive ... pace of consumer electronics human interface innovation. Synaptics, industry-leading ... for the automotive industry and will be implemented in ... Europe , Japan , and ...
(Date:11/2/2015)... MENLO PARK, Calif. , Nov. 2, 2015 /PRNewswire/ ... to $9 million to provide preclinical development services to ... Under the contract, SRI will provide scientific expertise, modern ... a wide variety of preclinical pharmacology and toxicology studies ... --> --> The PREVENT Cancer Drug ...
(Date:10/29/2015)... Calif. , Oct. 29, 2015  The J. ... new report titled, "DNA Synthesis and Biosecurity: Lessons Learned ... the Department of Health and Human Services guidance for ... in 2010. --> ... it also has the potential to pose unique biosecurity ...
Breaking Biology News(10 mins):